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Introduction
The human disease mastocytosis is considered a myeloproliferative neoplasm (MPN) by WHO (1). 
This disease is characterized by accumulation of  abnormal numbers of  mast cells in the skin and var-
ious organs. Oncogenic forms of  KIT are commonly found in patients with mastocytosis; they result 
in constitutive autophosphorylation, activation of  downstream signaling, and constitutive growth in 
the absence of  its ligand, stem cell factor (SCF) (2–4). The majority (~90%) of  mastocytosis patients 
harbor a particular point mutation in exon 17 (D816V in humans and D814V in mice) of  the KIT 
receptor (2, 5). We and others have shown that expression of  D816V or D814V in human or mouse 
cells, respectively, results in enhanced growth in vitro and transformation in vivo (6–8). A significant 
degree of  clinical heterogeneity exists in mastocytosis patients bearing the oncogenic form of  KITD816V 
mutation. In spite of  an abundant presence of  KITD816V mutation in all forms of  mastocytosis, target-
ing KITD816V alone has not been effective (9, 10).
Somatic mutations in ten-eleven-translocation 2 (TET2) have been described in patients with system-
ic mastocytosis (SM), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) (11–13). 
Interestingly, the mutational frequency of  TET2 is highest in SM patients (~30%), in particular in patients 
who have additional non–mast cell lineage neoplasm (AHNMD) (11). Furthermore, TET2 mutations have 
been shown to cosegregate with KITD816V mutation in patients with SM, and we have recently demonstrat-
ed poor overall survival of  SM patients harboring TET2 mutations (14). The major role of  TET family 
members is to oxidize 5-methyl cytosine (5-mC) to 5-hydroxy-mC (5-hmC) (12, 15, 16). TET2 mutations 
Mutations in KIT and TET2 are associated with myeloid malignancies. We show that loss of TET2-
induced PI3K activation and -increased proliferation is rescued by targeting the p110α/δ subunits 
of PI3K. RNA-Seq revealed a hyperactive c-Myc signature in Tet2–/– cells, which is normalized by 
inhibiting PI3K signaling. Loss of TET2 impairs the maturation of myeloid lineage–derived mast 
cells by dysregulating the expression of Mitf and Cebpa, which is restored by low-dose ascorbic acid 
and 5-azacytidine. Utilizing a mouse model in which the loss of TET2 precedes the expression of 
oncogenic Kit, similar to the human disease, results in the development of a non–mast cell lineage 
neoplasm (AHNMD), which is responsive to PI3K inhibition. Thus, therapeutic approaches involving 
hypomethylating agents, ascorbic acid, and isoform-specific PI3K inhibitors are likely to be useful 
for treating patients with TET2 and KIT mutations.
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associated with MPNs have been shown to impair TET2’s catalytic activity and result in reduced 5-hmC 
levels in patient-derived cells. Thus, TET proteins play an essential role in regulating the epigenetic sta-
tus of  genes in cells in which they are expressed; however, how TET2 functions in MPNs as well as the 
mechanisms by which TET2 loss of  function cooperates with other mutations, including KIT, to promote 
malignant transformation is poorly understood.
Treatment strategies and approaches to modulate the effect of  loss of  TET2-mediated changes in mast 
cells either alone or in combination with activating KIT mutation have not been investigated in significant 
detail, although recent studies have begun to shed some light on this (17, 18). Here, we have built and 
extended on these findings and provide detailed analysis of  TET2-deficient mast cells, therapeutic targets, 
approaches to inhibit, and the potential mechanisms by which loss of  TET2 cooperates with activating Kit 
mutation to enhance the transforming ability of  hematopoietic stem and progenitor cells.
Results
Evaluation of  TET2 expression in BM-derived mast cells and analysis of  5-hmC levels. We have previously reported 
targeted Tet2 reporter mice (19). The targeted alleles result in transcription of  nuclear GFP (nGFP) (Tet2: 
nGFP) mRNA instead of  Tet2 (endogenous ATG was disrupted). Heterozygous Tet2: nGFP (Tet2+/–) mice 
were interbred to obtain homozygous Tet2: nGFP (Tet2–/–) mice. GFP expression in BM cells collected 
from Tet2: nGFP mice correlates with endogenous TET2 expression (19). We generated BM-derived mast 
cells (BMMCs) from Tet2: nGFP mice and confirmed the expression of  TET2 by flow cytometry (Figure 
1A; x axis). Dot blot assays revealed a reduction in the levels of  5-hmC in Tet2–/– BMMCs compared with 
WT BMMCs (Figure 1B). These data reveal that BMMCs with TET2 deficiency have reduced levels of  
5-hmC within their genomic DNA.
In mice, the peritoneal cavity is a large source of  mast cells. We therefore quantified mast cells in the 
peritoneal cavity of  WT and Tet2–/– mice. A significant increase in the number of  IgE receptor and KIT 
receptor–positive mast cells was observed in Tet2–/– mice relative to controls (Figure 1C). Although flow 
cytometry revealed an increase in the total number of  IgE receptor–positive mast cells in Tet2–/– mice, they 
were of  an immature phenotype, representing promastocytes similar to those found in fetal blood (20). This 
was reflected by a decrease in the expression of  the high-affinity IgE receptor on Tet2–/– mast cells relative 
to controls (Figure 1C). No significant changes in other myeloid lineages were observed (data not shown). 
These results suggest the possibility that constitutive loss of  TET2 in BM cells may not only enhance the 
proliferation of  mast cells, but also partially block their maturation. Similar findings have been described in 
stem cell leukemia–deficient mast cells (21).
Figure 1. Deficiency of TET2 results in reduced 
5-hmC levels and increased numbers of immature 
promastocytes in the peritoneal cavity. (A) BM 
collected from WT or Tet2: nGFP mice was cultured 
in vitro to generate BMMCs. Flow cytometric 
quantification of GFP-positive cells is shown. GFP 
expression reflects the quantity of TET2 loss in 
these cells and, thus, confirms TET2 depletion in 
BMMCs. (B) WT and Tet2–/– BMMCs were subjected 
to DNA dot blot analysis to assess global 5-hmC 
levels, as described in the Methods. (C) Cells collect-
ed from the peritoneal cavity of WT and Tet2–/– mice 
were stained with an antibody that recognizes the 
high-affinity IgE receptor and subjected to flow 
cytometry. The percentage of IgE receptor–positive 
cells is indicated in the histograms. Quantification 
of the percentage IgE receptor–positive cells in 
histogram and quantification of absolute number of 
mast cells that are double positive for IgE receptor 
and KIT receptor cells is shown. n = 3, mean ± SD, 
*P < 0.05, unpaired, 2-tailed Student’s t test.
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Figure 2. BMMCs derived from WT and Tet2–/– mice were subjected to RNA isolation for transcriptome sequencing. (A) Heatmap of FPKM values for 
mast cell–specific genes that were differentially expressed (P < 0.05 and >1.5-fold increase or <−1.5-fold decrease in gene expression) in Tet2–/– cells 
compared with WT mast cells is shown. (B) RNA-Seq data obtained from 3 independent WT and Tet2–/–  BMMCs was subjected to Ingenuity pathway 
analysis (IPA), and major canonical signaling pathways, which were significantly modulated, are shown. (C) FPKM values for c-Myc mRNA transcript 
levels in RNA-Seq data obtained from WT and Tet2–/–  BMMCs is shown in graph. n = 3, mean ± SD, *P < 0.05. (D) Heatmap of FPKM values for genes 
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Genome-wide transcriptome analysis. In an effort to better understand the role of  TET2 in mast cell 
regulation, we performed RNA-sequencing (RNA-Seq) analysis on BMMCs derived from WT and 
Tet2–/– mice. Several genes were upregulated in Tet2–/– cells compared with controls (240 genes, P < 
0.05, >1.5-fold). Likewise, a much larger pool of  genes was downregulated in Tet2–/– cells relative to 
controls (465 genes, P < 0.05, <–1.5-fold). Expression of  genes required for mast cell functions, such 
as Tpsb2 (mast cell tryptase β 2), Tpsg1 (mast cell tryptase γ 1), Cma1 (mast cell chymase 1), Cpa3 (mast 
cell carboxypeptidase A), and Mcpt4 (mast cell protease 4), was significantly repressed in Tet2–/– cells 
compared with WT controls (Figure 2A). Furthermore, expression of  genes important for mast cell 
differentiation/maturation, such as Gata1, Mitf, and Kit, was also reduced in Tet2–/– cells compared 
with controls. Cebpa expression was higher in Tet2–/– cells relative to controls (Figure 2A). Expression 
of  C/EBPα is associated with basophil maturation and is downregulated as mast cells differentiate 
(22, 23). Supplemental Table 1 (supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.94679DS1) shows the log2-transformed fragments per kilobase per million 
reads mapped (FPKM) values for the genes shown in the heatmap in Figure 2A.
We next assessed the RNA-Seq data for molecular interaction networks and biological pathways 
using “cytoscape analysis.” Positively regulated pathway interactions were extrapolated with inclusion 
of  genes that were upregulated (240 genes, P < 0.05, >1.5-fold) in Tet2–/– cells compared with controls. 
Likewise, negatively regulated pathway interactions were deduced by cytoscape analysis on the pool 
of  genes that were downregulated in Tet2–/– cells relative to controls (465 genes, P < 0.05, <–1.5-fold). 
Pathway interactions involving cellular response networks, such as inflammatory response, migration, 
growth, proliferation, and antiapoptosis, were all positively regulated in Tet2–/– cells compared with 
controls (Supplemental Figure 1A). Among the negatively regulated pathways, the differentiation path-
way was most negatively affected as well as genes involved in negative regulation of  cell proliferation 
and phosphorylation (Supplemental Figure 1B). Ingenuity pathway analysis (IPA) of  RNA-Seq data 
revealed that loss of  TET2 modulates multiple signaling pathways in mast cells. We found a signifi-
cant upregulation in the genes associated with EIF2 signaling, p70SK6 signaling, mTOR signaling, 
and PI3K signaling, among other pathways (Figure 2B). We also found a significant increase in the 
expression of  c-Myc oncogene in Tet2–/– cells, and IPA analysis suggested c-MYC to be a major signaling 
molecule activated in Tet2–/– cells with an activation Z score of  5.5 (Figure 2C and Table 1). Importantly, 
RNA-Seq data analysis revealed that several direct targets of  c-MYC were also significantly upregulated 
as well as repressed in Tet2–/– cells relative to controls (Figure 2D). A significant number of  c-MYC–
regulated genes are involved in ribosome and ribonucleoprotein biogenesis as well as in RNA binding 
and metabolic processes. Supplemental Table 2 shows the log2-transformed FPKM values for the genes 
shown in the heatmap in Figure 2D. Given that c-MYC can control both cell cycle and cell survival, we 
conducted gene set enrichment analysis (GSEA) for genes involved in regulating cell cycle and apop-
tosis. Genes involved in regulating the cell cycle pathway were substantially enriched in Tet2–/– cells 
compared with controls with a normalized enrichment score (NES) of  5.6 (Figure 2E). Furthermore, 
apoptosis-promoting genes were negatively enriched in Tet2–/– cells with an enrichment score (NES) of  
–3.5 (Figure 2E). Taken together, deficiency of  TET2 is likely to impair the differentiation of  mast cells, 
resulting in increased proliferation and cell survival.
We next assessed precisely how loss of  TET2 affects mast cell development and functions. We subject-
ed WT and Tet2–/– BM cells to differentiation in the presence of  IL-3 to assess how loss of  TET2 (Tet2–/–) 
or Tet2 heterozygosity (Tet2+/–) might contribute to mast cell maturation using standard BMMC culture 
conditions (24). Flow cytometric quantification after week 1 of  culture showed no significant difference in 
IgE receptor and KIT receptor single-positive cells as well as KIT/IgE receptor double-positive cells when 
compared between different genotypes (Figure 3, A and B). However, cell differentiation assessment after 2 
weeks of  culture showed a significant decrease in KIT receptor single-positive cells and KIT/IgE receptor 
double-positive cells in Tet2+/– and Tet2–/– cells compared with WT cells, though no significant difference in 
IgE receptor–positive cells was observed. As shown in Figure 3A, WT BM cells matured normally, resulting 
in approximately 90% KIT/IgE receptor double-positive mast cells by the end of  third week of  culture. In 
involved in direct transcriptional regulation by c-Myc (P < 0.05 for >1.5-fold increase or <−1.5-fold decrease in gene expression) in Tet2–/– cells com-
pared with WT mast cells is shown. (E) GSEA on RNA-Seq data obtained from WT and Tet2–/–  BMMCs. Enrichment plots for cell cycle (NES = 5.6) and 
apoptosis (NES = –3.5) pathways are shown.
5insight.jci.org   https://doi.org/10.1172/jci.insight.94679
R E S E A R C H  A R T I C L E
contrast, during this same period, the maturation of  BM cells derived from Tet2+/– and Tet2–/– mice was 
significantly impaired in a Tet2 gene dosage-dependent manner, with a significant increase in the expression 
of  IgE receptor and KIT receptor single-positive cells and a profound reduction in the presence of  KIT/
IgE receptor double-positive cells (Figure 3B). Similar findings were recently reported in a slightly differ-
ent model of  TET2 deficiency (18). Figure 3C shows cytospins from WT and Tet2–/– cultures. One can 
observe the presence of  immature mast cells lacking characteristic mast cell granules in cultures derived from 
Tet2–/– mice compared with controls. Consistent with these findings, expression of  mast cell–specific genes, 
including Kit, while showing robust expression in WT BMMCs, showed significant reduction in Tet2–/– cells 
(Figure 2A and Figure 3D). Further, the expression of  c-Myc in Tet2–/– cells was significantly increased rel-
ative to controls, thus validating our earlier RNA-Seq observations (Figure 3D). Importantly, loss of  TET2 
retained high expression of  Cebpa relative to controls. Given the enhanced c-Myc expression noted above 
in Tet2–/– cells, we examined the ability of  these cells to proliferate and survive relative to controls. As seen 
in Figure 3E, an increase in the proliferation of  BMMCs was observed relative to controls in a Tet2 gene 
dosage-dependent manner. Cytokine-independent survival of  BMMCs was assessed under conditions of  
short-term and long-term withdrawal of  cytokines. Flow cytometric analysis showed an increase in percent-
age cell survival in Tet2–/– cells relative to controls (Figure 3F). Taken together, an early loss of  TET2 in mast 
cell progenitors impairs their survival and proliferation capacity. These results support our in vivo findings 
in mice (Figure 1C).
Loss of  TET2 in BMMCs results in reduced PTEN expression and hyperactivation of  the PI3K/AKT/c-Myc 
pathway. To understand how c-MYC contributes to the enhanced growth and proliferation of  TET2-defi-
cient cells, we reexamined our IPA findings and focused on the PI3K/AKT pathway, given that this path-
way is dysregulated in TET2-deficient cells (Figure 2B). A link between PI3K/AKT pathway and c-MYC 
has been described previously (25). PTEN loss–induced activation of  PI3K/AKT pathway drives B cell 
lymphoma transformation by upregulating c-MYC expression (26). In T-ALL, co-occurrence of  c-MYC 
overexpression and PTEN deficiency is commonly seen (27). We found an increase in the activation of  
AKT as well as ERK/MAPK pathway and an increase in phosphorylated S6 kinase in Tet2–/– cells (Figure 
4, A and B). Given the role of  PI3K/AKT in regulating the growth of  mast cells and the observed hyper-
sensitivity of  Tet2–/– cells to cytokine stimulation that resembles that of  PTEN-deficient mast cells (28), we 
hypothesized that the increase in AKT activation and growth in Tet2–/– mast cells may in part be due to 
impaired or reduced expression of  PTEN (28). We observed reduced expression of  PTEN protein and Pten 
mRNA in Tet2–/– cells relative to WT controls (Figure 4, C and D). PTEN expression in Tet2–/– cells was 
rescued to WT levels in the presence of  5-azacytidine, a hypomethylating agent (Figure 4E). The decrease 
in the expression of  PTEN was a result of  hypermethylated Pten promoter in Tet2–/– cells (Figure 4F).
PI3Ks are heterodimeric lipid kinases that are composed of  regulatory and catalytic subunits. The three 
catalytic subunits include p110α, p110β, and p110δ. All three catalytic subunits dimerize with the p85 regu-
latory subunit. The p85 subunit binds to p110 catalytic subunits, resulting in the conversion of  PIP2 to PIP3. 
PTEN opposes the activation of  this pathway by converting PIP3 back to PIP2 (29). To assess the role of  
the p85 regulatory subunit and the three catalytic subunits of  PI3K in cytokine-induced hypersensitivity in 
Table 1. List of major signaling molecules predicted to be activated in Tet2–/– mast cells (Ingenuity pathway analysis)
Upstream regulator Molecule type Activation Z score P value of overlap
MYC Transcription regulator 5.483 5.41 × 10–64
TNF Cytokine 2.234 1.03 × 10–53
TGFB1 Growth factor 2.177 1.27 × 10–53
IFNG Cytokine 2.606 4.86 × 10–49
IL4 Cytokine 4.367 6.64 × 10–46
IL1B Cytokine 2.308 1.32 × 10–39
CSF2 Cytokine 2.846 5.24 × 10–32
IL6 Cytokine 2.456 6.72 × 10–29
IL13 Cytokine 3.219 8.29 × 10–26
MYCN Transcription regulator 3.595 4.19 × 10–25
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Figure 3. Loss of Tet2 alters mast cell differentiation, development, and proliferation in a gene dosage-dependent manner. (A) BM cells were harvest-
ed from WT, Tet2+/–, and Tet2–/– mice, and BMMCs were generated. Cells were harvested after 1 week, 2 weeks, or 3 weeks of culture and stained with 
antibodies that recognize KIT and IgE receptor followed by flow cytometry. The percentage of cells double positive for KIT and IgE receptor is shown in 
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TET2-deficient cells, we performed a series of  genetic intercrosses to obtain TET2-deficient mice lacking the 
expression of  p85 or heterozygous for all three p110 catalytic subunits or completely devoid all three p110 
catalytic subunits of  PI3K. BM from these mice was harvested, and mast cells were generated as described 
above and subjected to thymidine incorporation assay to assess the cell proliferation. Loss of  p85α in Tet2–/– 
cells significantly repressed cytokine-induced proliferation associated with TET2 deficiency (Figure 4G). 
Likewise, heterozygosity of  all three catalytic subunits of  p110 also significantly rescued the enhanced cell 
proliferation seen in Tet2–/– cells (Figure 4H). However, total loss of  all three p110 catalytic subunits com-
pletely repressed the proliferation noted in TET2-deficient cells to WT levels (Figure 4I).
As shown earlier, whole-transcriptome sequencing data suggest that c-MYC dependent transcriptional 
regulation is active in Tet2–/– cells. We first assessed the levels of  c-MYC protein and c-Myc mRNA in WT 
and TET2-depleted cells. There was an increase in both protein and mRNA levels in TET2-deficient cells 
compared with WT cells. Importantly, deletion of  p85α in Tet2–/– cells or pharmacologic inhibition of  
PI3K reduced the level of  c-MYC protein and c-Myc mRNA nearly to WT levels (Figure 5, A and B). We 
next validated downstream direct targets of  c-MYC that were shown earlier to be upregulated (Figure 2D 
and Supplemental Table 2) (30). Enolase 1 (Eno1), a glycolytic gene known to be activated upon c-MYC 
overexpression (31, 32), was significantly increased in Tet2–/– cells compared with WT controls. Similarly, 
there was reduced Eno1 expression in cells lacking p85α subunit of  class IA PI3K in the background of  
TET2 deficiency. Likewise, expression of  branched chain amino acid transaminase 1 (Bcat1) — a c-MYC 
target gene that when overexpressed promotes cell proliferation, migration, and invasion (33) — was high 
in Tet2–/– cells compared with WT cells; however, p85α deletion in the setting of  TET2 deficiency corrected 
Bcat1 mRNA expression to WT levels. Expression of  serine hydroxymethyltransferase 1 (Shmt1), a known 
gene with c-MYC binding sites on its promoter, was significantly upregulated in Tet2–/– cells but normalized 
to WT levels in the setting of  p85α deficiency (34). SHMT1 has a known function in tumor growth and 
migration. c-MYC is also known to transcriptionally repress the inhibitor of  differentiation 2 (ID2) and 
PTEN-induced putative kinase 1 (PINK1) (35, 36). We discovered that TET2 loss in BMMCs reduces 
the expression of  both Id2 and Pink1 (Figure 2D and Figure 5B). Nucleophosmin (NPM1) is an oncogene 
frequently associated with blood cell malignancies, such as AML and NOTCH1-driven CLL, that interacts 
with c-MYC to promote hyperproliferation and transformation (27, 37). c-MYC can directly bind to the 
NPM1 promoter and transcriptionally upregulate the expression of  NPM1 (37). Loss of  TET2 results in an 
increase in the expression of  Npm1 compared with controls, which is c-MYC dependent and is rescued to 
WT levels in the absence of  p85α (Figure 5B). We further verified c-MYC functionality in TET2-depleted 
cells using a shRNA-mediated c-Myc knockdown approach. Tet2–/– cells with c-Myc knockdown showed a 
2-fold reduction in cell proliferation when compared with control cells (Figure 5C).
Differential regulation of  c-Jun and JunB can modulate c-Myc transcription in an AKT activation–
dependent manner (38). Analysis of  the c-Myc promoter suggests that JunB competitively binds to AP-1 
sites on c-Myc promoter and inhibits its transcription. In contrast, in the absence of  JUNB, c-JUN binds to 
the same AP-1 sites and transcriptionally upregulates c-Myc expression. JUNB collaborates with other AP-1 
family members, such as FOS, with higher affinity and inhibits transcription. Thus, JUNB protein levels are 
likely to be involved in regulating c-Myc expression in Tet2–/– cells. We show by RNA-Seq and QRT-PCR 
validation a several-fold decrease in JunB and Fos mRNA expression in Tet2–/– cells relative to controls (Fig-
ure 5D), which is associated with increased c-MYC expression. Importantly, TET2 loss mediated repres-
sion of  JunB and Fos expression was reversed in the absence of  p85α. Thus, enhanced PI3K activity in 
TET2-depleted cells regulates c-Myc expression in part by removal of  JUNB/FOS-mediated transcriptional 
inhibition. We validated JUNB-mediated c-Myc repression by overexpressing JunB in Tet2–/– cells. Tet2–/–-
top right quadrant of dot plot. Dot plot for 1 of 3 representative experiments is shown. (B) Flow cytometric quantification of IgE receptor–positive or KIT 
receptor–positive or IgE receptor and KIT receptor double-positive cells for WT, Tet2+/–, and Tet2–/– genotypes is shown. *P < 0.05, n = 3, mean ± SD. (C) 
Cytospin images of BMMCs from the indicated genotypes (original magnification, ×400). (D) Tet2, Cebpa, c-Myc, and Kit mRNA levels relative to β-actin 
mRNA levels in WT and Tet2–/– BMMCs were measured using QRT-PCR. *P < 0.05, n = 3, mean ± SD. (E) BMMCs from WT, Tet2+/–, and Tet2–/– mice were 
starved of serum/cytokines for 6 hours and cultured in the presence or absence of IL-3 for 48 hours, and cell proliferation was evaluated by [3H] thymidine 
incorporation. Counts per minute (CPM) are shown. n = 3, mean ± SD, *P < 0.05. Similar results were observed in 3 independent experiments. (F) BMMCs 
from WT and Tet2–/– mice were cultured in the absence of serum/cytokines for 18 hours or 48 hours, and these cells were stained with annexin V and 7-AAD 
followed by flow cytometry analysis. Representative dot plot of 3 independent experiments is shown. Flow cytometry quantification of percentage cell 
survival (annexin V and 7-AAD double negative) after 48 hours of cytokine withdrawal is shown. n = 3, mean ± SD, *P < 0.05. One-way ANOVA analysis (B) 
and unpaired, 2-tailed Student’s t test (D–F) methods were used for statistical analysis.
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JunB-GFP cells showed a significant reduction in c-Myc expression compared with empty vector harboring 
cells (Figure 5E). Collectively, these results suggest that hyperactivation of  the PI3K/c-MYC pathway con-
tributes markedly to the enhanced proliferation and survival of  TET2-deficient cells.
We next wanted to determine if  the mast cell maturation/differentiation defect observed in Tet2–/– 
cells could also be rescued in the absence of  PI3K catalytic subunits. BM cells derived from WT, Tet2–/–, 
Figure 4. Deficiency of TET2 in BMMCs results in PI3K activation. (A) AKT (ser473), phosphorylated ERK1/2, and total ERK1/2 levels in WT and Tet2–/– BMMCs. 
Representative data from 3 independent experiments are shown. (B) Western blots for S6 kinase and phosphor S6 kinase protein levels in WT and Tet2–/– BMMCs 
are shown. Representative data from 3 independent experiments are shown. (C) Western blots for PTEN and β-actin protein levels in WT and Tet2–/– BMMCs are 
shown. Data from 2 experiments from a total 3 independent experiments are shown. Quantification of PTEN and β-actin protein band densities is shown. n = 3, 
mean ± SD, *P < 0.05. (D) Pten mRNA levels in WT and Tet2–/– BMMCs were measured using QRT-PCR. n = 3, *P < 0.05, mean ± SD. (E) WT and Tet2–/– BMMCs 
were treated with 0.5 μM 5-azacytidine for 24 hours and subjected to Western blot analysis. PTEN and β-actin protein levels are shown. (F) Bisulfite-converted 
genomic DNA from WT and Tet2–/– BMMCs was used for Pten promoter methylation analysis. Percentage methylation change in GC-rich Pten promoter region is 
shown. BMMCs from mice with indicated genotypes (G–I) were starved for 6 hours and cultured in the presence or absence of IL-3. After 48 hours, cell proliferation 
was evaluated by [3H] thymidine incorporation. Counts per minute (CPM) are shown. n = 3, mean ± SD,*P < 0.05. mRNA levels were assessed relative to β-actin 
mRNA by QRT-PCR assay (C and D). Unpaired, 2-tailed Student’s t test (C and D) and 1-way ANOVA (G–I) were used for statistical analysis.
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p110α–/–β–/–δ–/–, and compound homozygous Tet2–/–:p110α–/–β–/–δ–/– mice were subjected to mast cell differ-
entiation analysis. While WT cells completely differentiated into KIT/IgE receptor double-positive cells 
by the end of  3 weeks of  culture, no rescue in the maturation of  Tet2–/– cells was observed at any time 
point examined under the tested conditions (Supplemental Figure 2). These results suggest that while loss 
Figure 5. Deficiency of TET2 in BMMCs induces c-MYC upregulation via PI3K activation. (A) c-MYC protein levels in BMMCs from WT, Tet2–/–, and 
Tet2–/–:p85α–/– mice were assessed. A representative experiment from 3 independent experiments is shown. Cell lysates collected from Tet2–/– cells that 
were treated with or without 0.5 μM GDC-0941 (p110αδ-specific PI3K inhibitor) for 12 hours were subjected to Western blot analysis using an anti–c-MYC 
antibody. A representative experiment from 3 experiments is shown. (B and D) c-Myc, Eno1, Bcat1, Shmt1, Npm1, Id2, Odc1, Tet2, Fos, and JunB mRNA lev-
els in BMMCs from WT, Tet2–/–, and Tet2–/–:p85α–/– mice were measured using QRT-PCR. *P < 0.05, n = 3, mean ± SD. (C) c-Myc mRNA knockdown in Tet2–/– 
BMMCs was achieved using Myc shRNA. Luciferase shRNA was used as a control. Shown are c-Myc knockdown levels, as assessed by QRT-PCR. These 
Myc-shRNA– and Luc-shRNA–harboring cells were starved for 6 hours and cultured in the presence or absence of IL-3. After 48 hours, cell proliferation was 
evaluated by [3H] thymidine incorporation. Counts per minute (CPM) are shown. n = 3, mean ± SD, **P < 0.05. (E) Retroviral JunB-GFP construct was trans-
duced into Tet2–/– BMMCs and sorted for GFP-positive cells, and c-Myc mRNA levels were measured using QRT-PCR. mRNA levels were assessed relative to 
β-actin mRNA by QRT-PCR assay (B–E). One-way ANOVA (B and D) and unpaired, 2-tailed Student’s t test (C and E) were used for statistical analysis.
1 0insight.jci.org   https://doi.org/10.1172/jci.insight.94679
R E S E A R C H  A R T I C L E
of  TET2-induced hyperproliferation could be rescued by inhibiting the catalytic subunits of  PI3K, inhibi-
tion of  this pathway had little effect on the impaired differentiation associated with TET2 loss.
Given that TET2 regulates global 5-hmC levels and thus may have an effect on the methylation and 
expression of  mast cell–specific transcription factors involved in regulating maturation/differentiation, we 
treated these cells with a FDA-approved hypomethylating agent, 5-azacytidine. As seen in Figure 6A, treat-
ment of  Tet2–/– BMMCs with 5-azacytidine (200 nM) completely restored the maturation of  these cells 
to WT levels, as assessed by the acquisition of  KIT/IgE receptor double-positive cells. The rescue in the 
maturation of  Tet2–/– BMMCs was associated with renewed expression of  Mitf, repression of  c-Myc, and 
increased expression of  Kit (Figure 6B). However, the expression of  some additional genes, such as Gata2, 
remained unaltered under these culture conditions.
Recent studies have shown that vitamin C can regulate the activity of  TET proteins, including those in 
mast cells (18, 39, 40). We looked to assess how low-dose vitamin C (25 μg/ml) alone or in combination 
with low dose 5-azacytidine (100 nM) might affect the maturation of  TET2-deficient mast cells. We ratio-
nalized that vitamin C treatment of  Tet2–/– BMMCs would increase the activity of  Tet1 or Tet3, thereby 
enhancing the conversion of  5-mC to 5-hmC, and that 5-azacytidine would inhibit the activation of  DNA 
methyl transferase (DNMT), thereby generating less 5-mC. As shown in Figure 7, A and B, treatment of  
Tet2–/– BMMCs with low-dose 5-azacytidine (half  the amount used in Figure 6A) alone partially restored 
the differentiation defect in these cells. Likewise, low-dose vitamin C treatment alone greatly improved the 
maturation of  TET2-deficient BMMCs. In contrast, the combined treatment using low-dose 5-azacytidine 
and vitamin C had a dramatic effect and completely rescued mast cell maturation, including the correction 
in hyperproliferation associated with TET2 deficiency (Figure 7, A–C). Figure 7C shows the effect of  com-
bined treatment of  these cells with 5-azacytidine and vitamin C on the proliferation of  Tet2–/– BMMCs. 
Combined treatment with vitamin C and 5-azacytidine resulted in significant changes in the expression of  
genes normally associated with mast cell maturation (Figure 7D). While the rescue in the expression of  
Figure 6. 5-Azacytidine treatment rescues mast cell differen-
tiation in TET2-depleted BM cells. (A) BM cells derived from 
WT and Tet2–/– mice were cultured in the presence or absence of 
5-azacytidine (200 nM) for 3 weeks. Cells were harvested and 
stained with antibodies that recognize KIT and IgE receptor after 
the indicated weeks, followed by flow cytometry. The percentage 
of cells positive for both KIT and IgE receptor expression is shown 
in top right quadrant of dot plot. A representative from 3 inde-
pendent experiments is shown. (B) c-Myc, Kit, Mitf, Gata1, and 
Gata2 mRNA levels in BM cells cultured for 3 weeks, as in A, were 
measured using QRT-PCR. mRNA levels relative to β-actin mRNA 
measured by QRT-PCR assay are shown. *P < 0.05, n = 3, mean ± 
SD, unpaired 2-tailed Student’s t test.
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some of  the genes associated with mast cell maturation was comparable in Tet2–/– cells that were treated with 
vitamin C alone or with a combination of  vitamin C and 5-azacytidine; combination treatment yielded the 
most repression in the expression of  Cebpa and Pu.1 compared with any other treatment group (Figure 7D).
TET2 mutations are frequent in patients with mastocytosis. In most cases, these mutations are associat-
ed with activating KIT (KITD816V) and confer overall poor prognosis. It is, however, unclear how the timing 
of  acquisition of  these mutations affects the development of  myeloid malignancies, given that the combi-
nation of  these mutations in patients is most often observed in SM with secondary non–mast cell hemato-
logic malignancies. We therefore generated mice heterozygous for the expression of  Tet2 (Tet2+/–; to mimic 
patient conditions), in which the expression of  activating KIT (KITD814V) was spatially, temporally, and 
conditionally regulated. Mx-Cre mice were crossed with the above knockin mice to obtain hematopoietic 
specific Cre-recombinase expression. Six to eight-week-old knockin mice were intraperitoneally injected 
with 300 μg of  polyI:C 3 times. Mice were analyzed after 12 to 16 weeks after polyI:C injections. As seen in 
Figure 8A, we observed an aggressive form of  MPN characterized by increased frequency of  lineage-neg-
ative Sca-1+ KIT+ cells in the BM and an increase in the frequency of  Gr-1/Mac-1 double-positive myeloid 
cells in the BM, peripheral blood, and spleen, with associated splenomegaly in compound heterozygous 
mice relative to controls. BM from these mice and additional controls, including WT and Tet2+/– mice, was 
Figure 7. Combination of 5-azacytidine 
and vitamin C treatment rescues mast 
cell differentiation and proliferation 
in TET2-depleted BM cells. (A) BM cells 
derived from WT and Tet2–/– mice were 
cultured in the presence or absence of 
5-azacytidine (100 nM) or vitamin C (25 μg/
ml) or in the presence of both 5-azacyti-
dine (100 nM) and vitamin C (25 μg/ml) for 
3 weeks. Cells were harvested and stained 
with antibodies that recognize KIT and 
IgE receptor, followed by flow cytometry. 
The percentage of cells double positive for 
KIT and IgE receptor is shown in the dot 
plot. (B) Quantitative assessment of the 
percentage of cells that are double positive 
for KIT and IgE receptor in A is shown. n = 
3, mean ± SEM, *P < 0.05. (C) BM derived 
from WT and Tet2–/– mice was cultured in 
the presence or absence of 5-azacytidine 
(100 nM) plus vitamin C (25 μg/ml) for 3 
weeks. After 3 weeks, these cells were 
starved for 6 hours and cultured for 48 
hours in the presence of IL-3 (10 ng/ml). 
After 48 hours, proliferation was evaluated 
by [3H] thymidine incorporation. Counts per 
minute (CPM) are shown. n = 3, mean ± SD, 
*P < 0.05. (D) BM cells derived from Tet2–/– 
mice were cultured, as in A. mRNA levels 
of indicated transcripts were measured 
by QRT-PCR. mRNA levels are relative to 
β-Actin mRNA levels, as measured by QRT-
PCR assay. n = 3, mean ± SD, * P < 0.05, 
unpaired, 2-tailed Student’s t test.
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harvested and subjected to mast cell differentiation in vitro. As seen in Figure 8B and consistent with our 
earlier observation, haploinsufficiency of  Tet2 results in reduced mast cell differentiation relative to con-
trols. In contrast, Tet2+/–:Kit+/D814V BMMCs demonstrated rapid and enhanced maturation relative to any 
other group, as indicated by the presence of  over 80% KIT/IgE receptor double-positive cells by the end 
of  third week of  culture. The increase in the maturation of  Tet2+/–:Kit+/D814V BMMCs was associated with 
a rescue in the expression of  Kit and Mitf and with a repression in the expression Cebpa relative to controls 
(Figure 8C). Not only did these cells show an increase in maturation, when subjected to a thymidine incor-
poration assay, a significant increase in the growth of  these cells in both IL-3 and SCF culture conditions 
was also observed (Figure 8D). These results suggest that the Tet2 haploinsufficiency–associated matura-
tion defect of  mast cells is rescued in the presence of  KitD814V mutation. However, KitD814V mutation confers 
SCF ligand–mediated proliferation to TET2-deficient cells.
Given the cooperation between oncogenic KIT and loss of  TET2 and the role of  PI3K catalytic sub-
units in regulating the proliferation of  TET2-deficient mast cells, we next assessed the specific contribution 
of  each of  these three p110 catalytic subunits utilizing pharmacologic and genetic approaches. We treated 
the cells with p110 isoform–specific inhibitors of  PI3K, including GDC-0941 (specific for p110α/δ), TGX-
221 (specific for p110β), and IC87114 (specific for p110δ). As seen in Figure 9, A and B, a significant reduc-
tion in the growth of  KitD814V+/–, Tet2+/–, and KitD814V+/–:Tet2+/– bearing cells was observed in the presence 
of  GDC-0941 and IL-3 or SCF but not in cells treated with TGX-221 or IC87114. Similar results were 
obtained when primary SM patient–derived cells were treated with the same combination of  drugs (Fig-
ure 9, D–F). To further confirm our pharmacologic findings and to specifically assess the role of  all three 
catalytic subunits of  PI3K in KitD814V induced growth, we used a genetic approach in which we generated 
BMMCs from mice lacking the expression of  specific isoforms of  p110 and their combinations. These cells 
were engineered to express KitD814V and subjected to proliferation analysis in the absence of  ligand stimu-
lation. As seen in Figure 9C and consistent with our pharmacologic findings shown in Figure 9, A, B, and 
D–F, combined loss of  p110α and p110δ subunits of  PI3K resulted in the most profound reduction in pro-
liferation of  KitD814V bearing cells. Taken together, our results show that, in addition to using various combi-
nations of  5-azacytidine and vitamin C, combined inhibition of  p110α and p110δ subunits of  PI3K is likely 
to be the most effective approach for treating MPN patients bearing activating KIT and TET2 mutations.
Discussion
In the current study, we have identified therapeutic targets for the treatment of  MPN involving KIT and TET2 
mutations. We show that the hyperproliferation caused by loss of  TET2 is significantly related to hyperacti-
vation of  the PI3K pathway. We also show that activating KIT mutation–induced ligand-independent growth 
utilizes a similar pathway (Figure 9C). Importantly, we show that cells that express oncogenic KIT and lack 
TET2 are also dependent on the PI3K pathway for proliferation. Thus, both oncogenic KIT and loss of  TET2 
induced signals converge on PI3K to regulate proliferation (Figure 10). We show using genetic and phar-
macologic approaches that the majority of  PI3K-dependent proliferation via these mutations is p110α and 
p110δ dependent, as cells lacking these genes and isoform-specific inhibitors against these catalytic subunits 
demonstrate maximum repression in proliferation. Thus, instead of  utilizing second- and third-generation 
TKI inhibitors, such as dasatinib and nilotinib, which show minimal efficacy in mastocytosis patients in vivo, 
perhaps using isoform-specific inhibitors of  PI3K might yield better therapeutic outcomes, at least in patients 
bearing a combination of  oncogene KIT and TET2 mutations (Figure 9E).
In addition to demonstrating an essential role for the PI3K pathway in regulating the growth of  cells 
bearing oncogenic Kit and loss of  TET2, we also provide evidence to suggest that use of  a hypomethylating 
agent, such as 5-azacytadine, is an alternate approach for treating patients with mastocytosis bearing TET2 
mutations. While others have described the use of  5-azacytidine for the treatment of  AML in murine mod-
els of  loss of  TET2 (41), our results in mast cells lacking TET2 show that the effect of  5-azacytidine treat-
ment on this lineage may be more profound compared with BM-derived hematopoietic stem/progenitor 
cells lacking TET2. We show that 5-azacytidine treatment of  BMMCs lacking TET2 not only completely 
restores the maturation defect, but also corrects the cytokine-induced hyperproliferation. We further show 
that a combination regimen of  low doses of  5-azacytidine and vitamin C has enhanced effect to further cor-
rect the TET2 deficiency–induced maturation and proliferation defects compared with either drug alone. 
Importantly, the combined treatment approach completely rescues the expression of  critical transcription 
factors and their downstream targets in these cells, including the ratio of Mitf to Cebpa (Figure 10).
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Figure 8. TET2 loss in cooperation with oncogenic KIT induced myeloproliferative neoplasm. (A) WT, Tet2+/–, and Tet2+/–:Kit+/D814V mice were intraper-
itoneally injected with poly(I:C), and mice were analyzed after 12–16 weeks of treatment. Flow cytometric quantification on BM cells was performed by 
staining the cells with KIT, Sca-1, and lineage-specific antibodies. The percentage of cells negatively selected for lineage markers, KIT positivity, and Sca-1 
positivity (LSK) is shown above inset boxes. Peripheral blood and BM cells were also analyzed by flow cytometry using Mac1, Gr1, and KIT antibodies, and 
the percentage of cells positive for Mac1 and Gr1 or cells positive for Mac1 and KIT is shown in dot blots. Spleen images of indicated genotypes are shown. 
Experiments were performed more than 3 times, and data from a representative experiment are shown. (B) BM-derived mast cells (BMMCs) were generat-
ed from WT, Tet2+/–, and Tet2+/–:Kit+/D814V mice described in A. Cells were harvested and stained with antibodies that recognize KIT and IgE receptor after the 
indicated weeks of culture, followed by flow cytometry analysis. The percentage of BMMCs double positive for KIT and IgE receptor expression are shown 
in dot blots. Representative of 3 independent experiments. (C) BMMCs as cultured in B were harvested, and Tet2, Kit, Cebpa, Mitf, and PU.1 mRNA levels, 
relative to β-actin mRNA levels, were measured using QRT-PCR. Mean ± SD, * P < 0.05. (D) BMMCs from mice with indicated genotypes were starved for 
6 hours and cultured in the presence or absence of IL-3 or SCF. After 48 hours, proliferation was evaluated by [3H] thymidine incorporation. Counts per 
minute (CPM) are shown. n = 3, mean ± SEM, *P < 0.05. One-way ANOVA test used for statistical analysis (C and D).
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Figure 9. PI3K inhibitor treatment decreases proliferation of KIT mutation-bearing mouse primary BM-derived mast cells with TET2 loss and in human SM 
patient samples. (A) BM-derived mast cells (BMMCs) derived from WT, Tet2+/–, Kit+/D814V, and Tet2+/–:Kit+/D814V mice were starved for 6 hours and cultured in the 
presence or absence of IL-3 (10 ng/ml) or SCF (30 ng/ml) in combination with increasing doses of GDC-0941 (p110α/δ-specific inhibitor of PI3K). After 48 hours, 
proliferation was evaluated by [3H] thymidine incorporation. Counts per minute (CPM) are indicated. n = 3, mean ± SD. *P < 0.05 compared with WT cells, **P 
< 0.05 compared with untreated Tet2+/– cells, ***P < 0.05 compared with untreated Kit+/D814V cells, ****P < 0.05 compared with untreated Tet2+/–:Kit+/D814V cells, 
unpaired 2-tailed Student’s t test. (B) WT and Tet2–/– BMMCs were transduced with KitD814V retroviral vector and sorted to homogeneity. These cells were treat-
ed with increasing doses of GDC-0941 (p110α/δ-specific), TGX-221 (p110β-specific), or IC87114 (p110δ-specific) inhibitors. After 48 hours, ligand-independent 
proliferation was evaluated by [3H] thymidine incorporation. CPM are shown. A representative experiment performed in quadruplicate is shown. Similar results 
were observed in 3 independent experiments. *P < 0.05 compared with untreated Tet2–/–-KitD814Vcells, **P < 0.05 compared with untreated WT-KitD814Vcells, 
unpaired 2-tailed Student’s t test. (C) KitD814V encoding retroviral vector was transduced into BMMCs that were deficient in the indicated catalytic subunits 
of PI3K. Sorted GFP-positive cells were subjected to thymidine incorporation assay in the absence of ligand stimulation. No GF, no growth factor. After 48 
hours, proliferation was evaluated by [3H] thymidine incorporation. CPM are shown. Data are from a single experiment performed in triplicates. Mean ± SEM, 
*P < 0.05 compared with WT-KitD814V, **P < 0.05 compared with p110α–/–β–/–-KitD814V, ***P < 0.05 compared with p110α–/–δ–/–-KitD814V, 1-way ANOVA analysis 
performed. (D–F) Growth of mastocytosis patient-derived (2 patients bearing both TET2 and KIT mutations and 2 KIT mutations but not TET2 mutation) cells 
in the presence of isoform-specific inhibitors of PI3K at indicated concentrations. Experiments were performed as described in B. Numbers on the x axis repre-
sent different patient samples. Experiments were performed in triplicates. Mean ± SEM, *P < 0.05, unpaired, 2-tailed Student’s t test.
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The relative balance between the expression of  transcription factors MITF and C/EBPα is likely to be 
essential for the observed defects associated with differentiation and growth seen in TET2-deficient BMMCs. 
To date, MITF is considered one of  the most critical transcription factors for specifying mast cell fate (23, 
42–44). MITF promotes a set of  mast cell–specific genes, including Kit, while simultaneously repressing a 
set of  basophil-specific genes, such as C/EBPα, while it does not affect T, B, eosinophil, neutrophil, or mac-
rophage development (22). Given that both MITF and C/EBPα can silence each other’s transcription in 
a directly antagonist fashion by binding to each others promoter, thus suppressing its respective promoter 
activity, this is likely to be the major reason for the correction in the maturation of  TET2-deficient BMMCs 
in the presence of  vitamin C and 5-azacytidine reported here. Taken together, our results suggest that TET2 is 
an upstream regulator of  mast cell and basophil lineage commitment, and, in its absence, C/EBPα expression 
is derepressed, which results in enhanced presence of  IgE receptor and Kit single-positive cells that appear to 
be stuck in an intermediary transition stage between basophils and mast cells. When the ratio of  MITF to C/
EBPα expression is modulated by treating these cells with a combination of  vitamin C and 5-azacytidine, the 
balance in the expression of  these factors is tipped in the favor of  MITF, which favors mast cell differentiation.
Studies have shown that vitamin C functions as a cofactor for Fe (II) 2-oxoglutarate dioxygenase 
enzymes, such as TET (39). Addition of  vitamin C promotes TET activity in cells. This results in a global 
increase in 5-hmC and DNA demethylation of  many gene promoters and upregulation of  many genes. 
Our findings in cells treated with vitamin C are in accordance with these observations and those recently 
reported in TET2-deficient mast cells and TET2 deficiency–associated leukemic cells (18, 45, 46). We also 
observed a partial correction in the differentiation of  Tet2–/– BMMCs in the presence of  vitamin C alone, 
which was associated with a significant but partial rescue in the expression of  several genes associated with 
mast cell maturation. Importantly, our results reveal that therapeutic efficacy of  hypomethylating agents 
can be enhanced when vitamin C is added at low levels. This cooperative effect is likely the result of  both 
passive DNA demethylation by low-dose 5-azacytidine treatment and active conversion of  5-mC to 5-hmC 
by TET1 and TET3 in the absence of  TET2 in these cells (47). Thus, addition of  vitamin C may be an 
efficient way to enhance the clinical effect of  hypomethylating agents for the treatment of  MPNs. Recent 
studies have utilized vitamin C to correct TET2 deficiency in hematopoietic stem and progenitor cells and 
block myeloid leukemia progression (45) and effect normal stem cell function (46).
Figure 10. Loss of TET2 and oncogenic KIT’s role in cell proliferation, survival, and transformation. Loss of TET2 reduces global 5-hmc levels, reduces Pten 
expression, and induces c-MYC expression, leading to hyperproliferation in BMMCs in a PI3K-dependent manner. Mast cells that express oncogenic KIT and 
lack TET2 are also dependent on the PI3K pathway for growth and proliferation. Loss of TET2 alters the expression of critical transcription factors, including 
C/EBPα and MITF, and essentially influences mast cell differentiation. Combined treatment approach with low doses of 5-azacytidine and vitamin C corrects 
TET2 deficiency–induced differentiation and proliferation defects in mast cells by altering the expression critical transcription factors, including the ratio of 
Mitf to Cebpa. In addition to using various combinations of 5-azacytidine and vitamin C, combined inhibition of p110α and p110δ subunits of PI3K is likely to 
be an effective approach for treating MPN patients bearing activating KIT and TET2 mutations.
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Our results in the context of  cooperation between oncogenic Kit and TET2 are somewhat in agree-
ment with previously reported findings but also distinct (17). We believe our mouse model truly mimics 
the human disease characterized by the development of  AHNMD. The differences in the two studies are 
likely to be due to the spatial and temporal expression of  TET2 and oncogenic Kit. In a previously reported 
study, both TET2 and oncogenic Kit were activated around the same time by polyI:C administration (17). 
In contrast, our studies, as in the human disease, in which loss of  TET2 is followed by the acquisition of  
oncogenic Kit mutations, demonstrate the development of  AHNMD. This is likely due to constitutive loss 
of  TET2 early on in hematopoietic stem/progenitor cells, which induces key changes in this compartment, 
which is further amplified by the late-onset acquisition of  oncogenic Kit, thus driving the development of  
AHNMD, similar to the human scenario. In this same model, we also demonstrated that oncogenic Kit 
expression in the background of  TET2 heterozygosity in BMMCs rescues the maturation defect associated 
with Tet2+/– mast cells, which is associated with complete rescue in the expression of  MITF and suppres-
sion of  C/EBPα. Thus, oncogenic Kit, through its ability to induce MITF expression (48), likely shifts the 
ratio of  MITF to C/EBPα in favor of  MITF, which by virtue of  its ability to antagonize C/EBPα, may 
drive mast cell maturation. We have previously shown the importance of  MITF in oncogenic KIT-induced 
growth and survival of  mast cells derived from patients (48).
Methods
Mice. Tet2: nGFP mice have been previously described (19). Mice harboring floxed p110α and p110β 
alleles and a p110δ D910A/D910A knockin allele were provided by Bart Vanhaesebroeck (University College 
London, London, United Kingdom). Floxed p85α mice have been previously described (49). Floxed 
p85α–/– mice were crossed with Tet2–/– mice to obtain Tet2–/–:p85α–/– double-knockout mice. Conditional 
KitD814V knockin mice have been described previously (50). Tet2–/– mice were crossed with KitD814V mice 
to obtain Tet2+/–:Kit+/D814V mice. Mx-Cre mice were crossed with above conditional knockout or knockin 
mice to obtain hematopoietic specific Cre-recombinase expression. Six- to eight-week-old conditional 
knockout or knockin mice were intraperitoneally injected with 300 μg polyI:C 3 times with 48-hour time 
intervals. Tet2+/–, KitD814V, and Tet2+/–:Kit+/D814V mice were analyzed 12–16 weeks after polyI:C injections. 
For BMMC generation, mice were euthanized after 4–6 weeks after polyI:C injection.
Cytokines, antibodies, and reagents. Recombinant murine IL-3 and SCF were purchased from Pepro 
Tech. Allophycocyanin-conjugated KIT antibody (17-1171-83), phycoerythrin-conjugated FcεR1 anti-
body (12-5898-82), PE-annexin V antibody (556422), and 7-amino actinomycin D (7-AAD) were pur-
chased from BD Biosciences. Anti–phospho-AKT (product no. 4060), anti–phospho-ERK (product no. 
4370), anti-AKT (product no. 9272), anti-ERK1/2 (product no. 9108), S6Kinase (product no. 2708), 
phosphor S6Kinase (product no. 9206), and anti-PTEN (product no. 9188) antibodies were purchased 
from Cell Signaling Technology and anti–β-actin antibody (A5316) was purchased from MilliporeSigma. 
RetroNectin was purchased from Takara. Iscove’s modified Dulbecco’s medium (IMDM) was purchased 
from Invitrogen. [3H] Thymidine was purchased from PerkinElmer. 5-Azacytidine and vitamin C were 
purchased from MilliporeSigma. PI3K inhibitor GDC-0941 was purchased from Selleck Chemicals, 
TGX-221 and IC87114 were purchased from Calbiochem. Puromycin was purchased from MilliporeSig-
ma. ImageJ software that used for protein band densitometry was obtained from the NIH repository 
(https://imagej.nih.gov/ij/download.html).
Generation of  BM-derived mast BMMCs. Low-density BM cells from WT mice and mice with indicated 
genotypes were cultured in the presence of  IL-3 (10 ng/ml) for 3–4 weeks.
Retroviral plasmid transduction in primary BMMCs. MIEG3 retroviral plasmid vector, WT Kit, and KitD814V 
cDNA expressing retroviral vectors were reported earlier (24). Myc-shRNA plasmid for c-Myc knockdown 
studies was gift from Martin Eilers (Universitat Wurzburg, Wurzburg, Germany) (Addgene plasmid 15662). 
Luc-ShRNA retroviral plasmid was gift from David Sabatini (Whitehead Institute for Biomedical Research, 
Cambridge, Massachusetts, USA) (Addgene plasmid 30324). JunB-MIEG3 plasmid was gift from Alexander 
Dent (Indiana University, Indianapolis, Indiana, USA) (Addgene plasmid 40349). Indicated retroviral plas-
mids were transfected into the Phoenix ecotropic packaging cell line using a calcium phosphate transfection 
kit (Invitrogen). Retroviral supernatants were collected after 48 hours of  transfection. Low-density BM cells 
(2 million) were plated in RetroNectin-coated sterile nontissue culture 6-well plates. 2 ml high-titer retroviral 
supernatants was added to these cells along with IMDM media containing 20% FBS and 2% penicillin-strep-
tomycin supplemented with 100 ng/ml SCF and 10 ng/ml IL-3. After 24 hours, a second round of  retroviral 
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infection was performed. 48 hours later, cells were sorted for GFP to homogeneity. shRNA RNA plasmid 
bearing cells were selected for puromycin resistance.
Analysis of  mast cell differentiation, proliferation, and apoptosis. Differentiation progress of mast cells was ana-
lyzed by examining the expression of Kit and IgE receptor using flow cytometry as described earlier (51). Prolif-
eration and apoptosis were assessed by conducting a thymidine incorporation assay as described previously (51).
Analysis of  intraperitoneal mast cells. 7 ml sterile PBS was injected intraperitoneally into mice and allowed 
to equilibrate for 5 minutes. A total of  5 ml peritoneal lavage was retrieved, and total cells were counted 
after red cell lysis. Cells were stained with antibody specific to high-affinity IgE receptor (FCeR1α receptor) 
and KIT receptor, followed by flow cytometric analysis.
Methylation analysis. Two micrograms genomic DNA isolated from WT and Tet2–/– BMMCs was used for 
bisulfite treatment using the EpiTect Bisulfite kit (Qiazen) according to the manufacturer’s instructions. Prim-
er sets used to amplify the Pten gene promoter region were designed using MethPrimer web tool (52). The 
PCR fragment for the Pten promoter region was generated using approximately 40 ng bisulfite-modified DNA 
and the following primers: forward, GGAAGTTGTAGTTATGATGGAAGTTTGAGAGTTG; reverse, 
AACCTACTTCTCCTCAACAACCAAAAACCTAAC. The resultant PCR fragment was cloned into pCR 
2.1 vector using the TA cloning kit (ThermoFisher Scientific) according to the manufacturer’s instructions. 
10–15 plasmid clones of  WT and Tet2–/– cells were sequenced using McLab DNA sequencing service. BiQ 
analyzer (53) was used to analyze the percentage methylation on the GC-rich region of  Pten promoter.
DNA dot blotting. Levels of  5-hmC in WT and Tet2–/– BMMCs were detected using dot blot as 
described previously (54). Genomic DNA isolated from WT and Tet2–/– BMMCs was added to denatur-
ation buffer (0.4 mM NaOH, 10 mM EDTA) and denatured for 10 minutes at 100°C. Samples were rap-
idly chilled for 5 minutes on wet ice, and then 2-fold serial dilutions of  DNA were applied to a positively 
charged nylon membrane under vacuum using a 96-well Dot Blot Hybridization Manifold (Bio-Rad). 
The membrane was washed twice in 2 × SSC buffer, UV cross-linked, and dried for 1 hour at 70°C. Mem-
brane was blocked with 5% nonfat dry milk for 1 hour and was probed with anti–5-hmC antibody (Active 
Motif) at 4oC overnight. Membrane was washed with TBS-T buffer and incubated with HRP-conjugated 
anti-mouse secondary antibody (1:5,000 dilution) for 1 hour at room temperature. After washing with 
TBS-T, membrane was visualized by enhanced chemiluminescence.
5-Azacytidine and vitamin C treatment. WT and Tet2–/– BMMCs were incubated with 5-azacytidine 
for 24 hours. Cells were collected, and equal amounts of  protein lysates were subjected to Western blot 
analysis using an anti-PTEN antibody or anti–β-actin antibody as indicated. To assess mast cell matu-
ration, WT and Tet2–/– BMMCs were cultured in the presence or absence of  indicated concentrations 
of  5-azacytidine and vitamin C.
QRT-PCR analysis. BMMCs collected from indicated genotypes were cultured in the presence of  IL-3 (10 
ng/ml) and indicated concentrations of  5-azacytidine and vitamin C. RNA was isolated using the Qiagen 
RNeasy plus mini kit according to manufacturer’s instructions. RNA was quantified using Nanodrop. RNA 
(4 μg) was used for cDNA preparation using a RNA-to-cDNA reverse transcription kit (Bioline). 2× Sensi-
Fast SYBR Green enzyme mix (Bioline) was used for quantitation of  mRNA levels by real-time PCR. PCR 
cycles and signal acquisition were performed using Agilent Mx3000P QPCR System thermal cycler (Agilent 
Technologies). Primers used for quantitation of  mRNA levels are provided in Supplemental Table 3.
Genome-wide transcript analysis using RNA deep sequencing. Mast cells were cultured as described above. 
RNA was isolated from cultured mast cells derived from 3 WT and 3 Tet2–/– mice and sequenced for genome-
wide transcript analysis using the llumina platform (Next Generation Sequencing Core at The Sidney Kim-
mel Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, USA). We collected the raw sequence 
reads (paired-end reads) and ensured the quality of  the reads using FastQC (default parameters). Raw 
sequences were checked for adaptor content and for high content of  any unknown bases (N) along the reads 
to obtain a final set of  clean reads. The data are specific to mast cells and have paired-end fragments with 
an average of  101 bp. Hierarchical indexing for Spliced Alignment of  Transcripts (HISAT) (55) was used to 
align quality filtered paired-end reads using default parameters against the whole-mouse reference genome 
mm10. Sequence Alignment Map (SAM) files, the output files from HISAT, were processed using SAMtools 
(version 0.1.19) (56) and subsequently used for the quantification of  transcript expression levels. In order to 
identify and quantify transcripts from RNA-seq reads, StringTie (version 1. 2. 1) (57) was used with default 
parameters to quantify the transcripts of  each genomic locus considering all possible multiple splice events. 
FPKM values for each gene were considered for further downstream analysis. Empirical analysis of  digital 
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gene expression data in R (Edge R) (58) package was used for differential gene expression analysis of  RNA-seq 
expression profiles. StringTie output of  genes and their respective FPKM values were converted to data 
matrix and, thereby, differentially expressed genes were identified. Log2-transformed fold changes in gene 
expression in Tet2–/– mast cells over WT mast cells were used to perform IPA using IPA software, a web- 
delivered application (https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/). 
Only genes that were differentially expressed with a FDR <0.01 were considered for further functional 
enrichment and GSEA, with a specific emphasis on genes involved in mast cell biology. Heatmap images 
were visualized using gitools (http://www.gitools.org/).
GSEA. GSEA (59) was performed using the default parameters, except the Enrichment Statistic Classic 
option was used as the weighted option, using GSEA desktop application (version 2.2.2). All the genes 
obtained from StringTie analysis with log fold changes and P values from EdgeR were included to construct 
a rank order by using a scoring metric (60). Eventually, we examined the upregulated or downregulated 
genes involved in biological processes from the KEGG database (61, 62).
Biological functional enrichment of  genes. CluGo (63), the open source plugin in Cytoscape, was used to 
comprehend and visualize enriched biological themes. Differentially expressed genes with P values of  less 
than 0.05 and FPKM values of  greater than 15 were included in the analysis to understand the signifi-
cance of  expressed transcripts in respective biological processes. Differentially expressed genes with log 
fold changes greater than 1.5 (for upregulated processes) and less than –1.5 (for downregulated processes) 
were considered.
Statistics. Statistical differences between 2 groups were determined using the unpaired Student’s t test 
with a 2-tailed distribution. One-way ANOVA was used in analyses involving multiple comparisons. P < 
0.05 was considered significant.
Study approval. All mice were maintained under specific pathogen–free conditions at the Indiana Uni-
versity Laboratory Animal Research Center (Indianapolis, Indiana, USA). All animal procedures were 
conducted in accordance with the Guide for the Care and Use of  Laboratory Animals (National Academies 
Press, 2011) and were approved by the Institutional Animal Care and Use Committees at Indiana Universi-
ty School of  Medicine. Samples from SM patients were collected after obtaining written informed consent 
in accordance with the Declaration of  Helsinki; sample use was approved by the IRB of  the Cleveland 
Clinic/Case Comprehensive Cancer Center and the IRB of  the Indiana University School of  Medicine.
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